PMID- 21342916 OWN - NLM STAT- MEDLINE DCOM- 20110713 LR - 20110504 IS - 1468-2060 (Electronic) IS - 0003-4967 (Linking) VI - 70 IP - 6 DP - 2011 Jun TI - Phosphodiesterase 4 (PDE4) regulation of proinflammatory cytokine and chemokine release from rheumatoid synovial membrane. PG - 1130-7 LID - 10.1136/ard.2010.134825 [doi] AB - BACKGROUND: The cAMP-metabolising enzyme, phosphodiesterase 4 (PDE4), has been implicated in a number of immune responses, including tumour necrosis factor alpha (TNFalpha) production. To date, few data have directly addressed whether synovial cytokine and chemokine production is modified by PDE4. OBJECTIVE: Using specific PDE4 inhibitors, roflumilast plus two novel inhibitors, INH 0061 and INH 0062, the authors studied the effect of PDE4 inhibition on proinflammatory cytokine and chemokine release from primary rheumatoid arthritis (RA) synovial digest suspensions and in a macrophage T cell co-culture assay system. RESULTS: All PDE4 inhibitors dose-dependently reduced the release of TNFalpha from primary synovial membrane cultures (n=5), half maximal inhibitory concentration (IC(50)) 300-30 nM, p<0.05. Similarly, a significant suppression in the release the proinflammatory chemokines, monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein (MIP)-1alpha, MIP-1beta (IC(50) 300-30 nM) and regulated upon activation normal T-cell expressed and secreted (RANTES) (IC(50) 3 nM) was also observed, p<0.05. While interleukin 1beta was also reduced, it did not achieve an IC(50). These observations were further confirmed in a macrophage T cell co-culture system, demonstrating the importance of PDE4 pathways in regulating cytokine/chemokine release in a cellular interaction implicated in inflammatory synovitis. Subsequent studies using the human monocytic cell line U937 also demonstrated cytokine regulation with PDE4 knockdown utilising a small interfering RNA approach. CONCLUSION: These data provide direct evidence of PDE4-dependent pathways in human RA synovial inflammatory cytokine and chemokine release and may provide a novel approach in treating chronic autoimmune conditions such as RA. FAU - Crilly, Anne AU - Crilly A AD - Institute of Infection, Immunity and Infl ammation, Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, UK. anne.crilly@glasgow.ac.uk FAU - Robertson, Susan E AU - Robertson SE FAU - Reilly, James H AU - Reilly JH FAU - Gracie, J Alastair AU - Gracie JA FAU - Lai, Wen-Qi AU - Lai WQ FAU - Leung, Bernard P AU - Leung BP FAU - Life, Paul F AU - Life PF FAU - McInnes, Iain B AU - McInnes IB LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20110221 PL - England TA - Ann Rheum Dis JT - Annals of the rheumatic diseases JID - 0372355 RN - 0 (Cytokines) RN - 0 (Inflammation Mediators) RN - 0 (Phosphodiesterase 4 Inhibitors) RN - 0 (RNA, Small Interfering) RN - EC 3.1.4.17 (Cyclic Nucleotide Phosphodiesterases, Type 4) SB - IM MH - Arthritis, Rheumatoid/enzymology/*immunology/pathology MH - Cell Communication/immunology MH - Cells, Cultured MH - Coculture Techniques MH - Cyclic Nucleotide Phosphodiesterases, Type 4/genetics/*physiology MH - Cytokines/biosynthesis/*metabolism MH - Dose-Response Relationship, Drug MH - Down-Regulation/drug effects MH - Humans MH - Inflammation Mediators/*metabolism MH - Phosphodiesterase 4 Inhibitors/pharmacology MH - RNA, Small Interfering/genetics MH - Synovial Membrane/drug effects/enzymology/*immunology MH - Synovitis/enzymology/immunology MH - T-Lymphocytes/drug effects/immunology EDAT- 2011/02/24 06:00 MHDA- 2011/07/14 06:00 CRDT- 2011/02/24 06:00 PHST- 2011/02/24 06:00 [entrez] PHST- 2011/02/24 06:00 [pubmed] PHST- 2011/07/14 06:00 [medline] AID - ard.2010.134825 [pii] AID - 10.1136/ard.2010.134825 [doi] PST - ppublish SO - Ann Rheum Dis. 2011 Jun;70(6):1130-7. doi: 10.1136/ard.2010.134825. Epub 2011 Feb 21.